BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25961594)

  • 1. MicroRNA networks regulated by all-trans retinoic acid and Lapatinib control the growth, survival and motility of breast cancer cells.
    Fisher JN; Terao M; Fratelli M; Kurosaki M; Paroni G; Zanetti A; Gianni M; Bolis M; Lupi M; Tsykin A; Goodall GJ; Garattini E
    Oncotarget; 2015 May; 6(15):13176-200. PubMed ID: 25961594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
    Paroni G; Fratelli M; Gardini G; Bassano C; Flora M; Zanetti A; Guarnaccia V; Ubezio P; Centritto F; Terao M; Garattini E
    Oncogene; 2012 Jul; 31(29):3431-43. PubMed ID: 22056878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-trans-retinoic Acid Modulates the Plasticity and Inhibits the Motility of Breast Cancer Cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ).
    Zanetti A; Affatato R; Centritto F; Fratelli M; Kurosaki M; Barzago MM; Bolis M; Terao M; Garattini E; Paroni G
    J Biol Chem; 2015 Jul; 290(29):17690-17709. PubMed ID: 26018078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.
    Centritto F; Paroni G; Bolis M; Garattini SK; Kurosaki M; Barzago MM; Zanetti A; Fisher JN; Scott MF; Pattini L; Lupi M; Ubezio P; Piccotti F; Zambelli A; Rizzo P; Gianni' M; Fratelli M; Terao M; Garattini E
    EMBO Mol Med; 2015 Jul; 7(7):950-72. PubMed ID: 25888236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid.
    Khan S; Wall D; Curran C; Newell J; Kerin MJ; Dwyer RM
    BMC Cancer; 2015 May; 15():345. PubMed ID: 25934412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.
    Tari AM; Lim SJ; Hung MC; Esteva FJ; Lopez-Berestein G
    Oncogene; 2002 Aug; 21(34):5224-32. PubMed ID: 12149644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-302b-inhibited E2F3 transcription factor is related to all trans retinoic acid-induced glioma cell apoptosis.
    Chen PH; Shih CM; Chang WC; Cheng CH; Lin CW; Ho KH; Su PC; Chen KC
    J Neurochem; 2014 Dec; 131(6):731-42. PubMed ID: 25040912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers.
    Alsafadi S; Even C; Falet C; Goubar A; Commo F; Scott V; Quidville V; Albiges L; Dieci MV; Guegan J; Lazar V; Ahomadegbe JC; Delaloge S; André F
    Clin Breast Cancer; 2013 Oct; 13(5):401-8. PubMed ID: 23830798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets.
    Terao M; Fratelli M; Kurosaki M; Zanetti A; Guarnaccia V; Paroni G; Tsykin A; Lupi M; Gianni M; Goodall GJ; Garattini E
    J Biol Chem; 2011 Feb; 286(5):4027-42. PubMed ID: 21131358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.
    Berardi DE; Flumian C; Campodónico PB; Urtreger AJ; Diaz Bessone MI; Motter AN; Bal de Kier Joffé ED; Farias EF; Todaro LB
    Cell Oncol (Dordr); 2015 Aug; 38(4):289-305. PubMed ID: 26044847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
    Hsiao YC; Yeh MH; Chen YJ; Liu JF; Tang CH; Huang WC
    Oncotarget; 2015 Nov; 6(35):37965-78. PubMed ID: 26513016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
    Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
    Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells.
    Jinno H; Steiner MG; Nason-Burchenal K; Osborne MP; Telang NT
    Int J Oncol; 2002 Jul; 21(1):127-34. PubMed ID: 12063559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4.
    Hayashi K; Goodison S; Urquidi V; Tarin D; Lotan R; Tahara E
    Int J Oncol; 2003 Mar; 22(3):623-9. PubMed ID: 12579317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
    Seidel J; Kunc K; Possinger K; Jehn C; Lüftner D
    Biochem Biophys Res Commun; 2011 Oct; 414(1):226-32. PubMed ID: 21945930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.
    Al-Qassab Y; Grassilli S; Brugnoli F; Vezzali F; Capitani S; Bertagnolo V
    BMC Cancer; 2018 Nov; 18(1):1194. PubMed ID: 30497437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.